0A43 Stock Chart & Stats
$1.30
$0.03(2.91%)
At close: 4:00 PM EDT
$1.30
$0.03(2.91%)
Day’s Range― - ―
52-Week Range$0.57 - $2.72
Previous CloseN/A
Volume34.22K
Average Volume (3M)48.20K
Market Cap
$96.01M
Enterprise Value$61.11M
Total Cash (Recent Filing)$36.67M
Total Debt (Recent Filing)$8.00M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Nov 10, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding103,397,514
10 Day Avg. Volume89,771
30 Day Avg. Volume48,200
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.39
Price to Sales (P/S)1248.52
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-40.75
Enterprise Value/Ebitda-0.95
Forecast
1Y Price Target
$3.17Price Target Upside143.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$666.67K
Bulls Say, Bears Say
Bulls Say
Regulatory Progress Toward Potential ApprovalProgress through late-cycle FDA review, completed inspections, and a defined PDUFA date reduces some development uncertainty and supports launch planning. If approval is granted, this milestone could convert the lead program from a development asset into a commercial revenue opportunity.
DNA Medicine Platform ValidationPositive partner Phase III results provide clinical validation for Inovio’s DNA medicine platform beyond its lead program. External success may strengthen confidence in the underlying technology, support future partnering interest, and improve the prospects for advancing additional candidates.
Operating Expense ReductionLower operating expenses indicate management is actively controlling the cost base while the company advances regulatory and commercial activities. Sustained discipline could extend available funding, reduce the rate of cash consumption, and preserve resources for priority programs and launch execution.
Bears Say
No Meaningful Product Revenue And Persistent LossesThe company has not yet established a self-sustaining commercial revenue base, leaving its financial performance dependent on development progress and external funding. Persistent operating losses indicate that future approval and commercialization milestones remain essential to improving earnings power.
Severe Cash Burn And Weakened Balance SheetOngoing negative operating and free cash flow means the business is not currently funding itself through operations. Combined with sharply reduced equity and higher leverage, this weakens financial flexibility and increases the importance of future financing or successful commercialization.
Material Approval And Confirmatory-trial UncertaintyEven with substantial review progress, the lead program remains exposed to unresolved FDA decisions before approval and after any accelerated pathway outcome. Uncertainty over confirmatory requirements could affect development costs, timing, labeling, and the durability of future commercial revenues.
Inovio Pharmaceuticals News
0A43 FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest share price was $0.57 and its highest was $2.72 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $96.01M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Nov 10, 2026 which is in 12 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Aug 12, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.217 by $0.147.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals does not currently pay dividends.
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.2.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 103,397,514 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.217. Following the earnings report the stock price went up 18.301%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0A43
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inovio Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.17 (143.59% Upside)
$3.17 (143.59% Upside)
Blogger Sentiment
Bullish
GB:0A43 Sentiment 67%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.25%
12-Months-Change
Fundamentals
Return on Equity
-1005.80%
Trailing 12-Months
Asset Growth
-27.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
0A43 Company Deck
0A43 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful progress on the regulatory front (target PDUFA date, completed inspections, an FDA informal meeting) and tangible commercial/pipeline milestones (partner Phase III success, DPROT preclinical progress, Syneos engagement). Financially the company cut costs and completed an $18.3M equity offering that extends runway into late Q1 2027. However, material risks remain: near‑term liquidity is tight with an $18M projected Q3 burn, net loss improvement was substantially driven by a noncash warrant gain, regulatory uncertainties persist around accelerated approval eligibility and confirmatory trial design feedback, and competitive uptake of a rival product exists. Taken together, positives around regulatory momentum and platform validation are balanced by financing, regulatory, and execution risks.View all GB:0A43 earnings summaries0A43 Stock 12 Month Forecast
Average Price Target
$3.17
▲(143.59% Upside)
Technical Analysis
Agenus
―
Oncolytics Biotech
―
―
Atossa Therapeutics
―
Anixa Biosciences
―
Instil Bio
―